Moreover, bioinformatics prediction and experimental validation also proved that miR-20a could be another new therapeutic agent for HCC through targeting cyclin D1 (Karimkhanloo et al., 2017) (Figure 1). The gene discussed is CCND1; the disease is hepatocellular carcinoma.